What does this research mean for the field?

The early cardiorenal benefits of SGLT2 inhibitors in heart failure are independent of glucose-lowering effects and are likely driven by a combination of multiple direct cardiac and systemic mechanisms that simultaneously target heart failure pathogenesis. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

July 14, 2020World Journal of DiabetesOpen Access

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

View Full Paper

Ask AI

Bookmark

Why the study?

Despite clinical cardiovascular and heart failure benefits of SGLT2 inhibitors extending to non-diabetic patients, their underlying mechanisms of action remain uncertain.

What are the mechanisms of action by which SGLT2 inhibitors reduce heart failure risk?

Design

Review

Authors

PRPetra Grubić Rotkvić MBMaja Cigrovski Berković NBNikola Bulj

Discussion

Member takes

Overview

Extends mechanistic understanding of SGLT2 inhibitors in HF; leaves open dominant pathway confirmation in prospective trials.

Structured PICO

What are the mechanisms of action by which SGLT2 inhibitors reduce heart failure risk?

Population

Patients with heart failure, including those with reduced ejection fraction, regardless of diabetes status

Intervention

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin)

This review summarizes the multiple proposed mechanisms by which SGLT2 inhibitors confer early cardiorenal benefits and reduce heart failure risk, independent of their glucose-lowering effects.

Cite This Study

Rotkvić et al. (2020) studied this question.

synapsesocial.com/papers/6a1bc9d51567d2fc4d5efea0 https://doi.org/10.4239/wjd.v11.i7.269

View Full Paper

Ask AI

Bookmark

July 14, 2020World Journal of DiabetesOpen Access

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure

View Full Paper

Ask AI

Bookmark

Why the study?

Despite clinical cardiovascular and heart failure benefits of SGLT2 inhibitors extending to non-diabetic patients, their underlying mechanisms of action remain uncertain.

What are the mechanisms of action by which SGLT2 inhibitors reduce heart failure risk?

Design

Review

Authors

PRPetra Grubić Rotkvić MBMaja Cigrovski Berković NBNikola Bulj

Discussion

Member takes

Overview

Extends mechanistic understanding of SGLT2 inhibitors in HF; leaves open dominant pathway confirmation in prospective trials.

Structured PICO

What are the mechanisms of action by which SGLT2 inhibitors reduce heart failure risk?

Population

Patients with heart failure, including those with reduced ejection fraction, regardless of diabetes status

Intervention

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin)

This review summarizes the multiple proposed mechanisms by which SGLT2 inhibitors confer early cardiorenal benefits and reduce heart failure risk, independent of their glucose-lowering effects.

Cite This Study

Rotkvić et al. (2020) studied this question.

synapsesocial.com/papers/6a1bc9d51567d2fc4d5efea0 https://doi.org/10.4239/wjd.v11.i7.269

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark